NEW YORK, NY / ACCESSWIRE / September 19, 2022 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.
Weber Inc. (NYSE:WEBR)
If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/weber-inc-loss-submission-form?prid=31879&wire=1
Lead Plaintiff Deadline: September 27, 2022
This lawsuit is on behalf of persons and entities that purchased or otherwise acquired Weber Class A common stock pursuant and/or traceable to the registration statement and prospectus issued in connection with the Company's August 2021 initial public offering.
Allegations against WEBR include that: (1) Weber was reasonably likely to implement price increases; (2) as a result, consumer demand for Weber's products was reasonably likely to decrease; (3) due to the resulting inventory buildup, Weber was reasonably likely to run promotions to 'enhance retail sell through' (4) the foregoing would adversely impact Weber's financial results; and (5) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.
Ampio Pharmaceuticals, Inc. (NYSE:AMPE)
If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/ampio-pharmaceuticals-loss-submission-form?prid=31879&wire=1
Lead Plaintiff Deadline: October 17, 2022
This lawsuit is on behalf of all persons or entities that purchased or otherwise acquired Ampio common stock between December 29, 2020 and August 3, 2022, inclusive.
Allegations against AMPE include that: (i) defendants had inflated the Company's true ability to successfully file a Biologics License Application ('BLA') for Ampion; (ii) defendants had inflated the results of the AP-013 study and the timing of unblinding the data from the AP-013 study; and (iii) as a result of the foregoing, defendants' statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Medtronic plc (NYSE:MDT)
If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/medtronic-lawsuit-loss-submission-form?prid=31879&wire=1
Lead Plaintiff Deadline: November 7, 2022
This lawsuit is on behalf of persons and entities who purchased or otherwise acquired Medtronic common stock between June 8, 2019, and May 25, 2022, inclusive.
Allegations against MDT include that: (1) Medtronic's product quality control systems were inadequate; (2) Medtronic had failed to comply with numerous regulations regarding risk assessment, corrective and preventive action, complaint handling, device recalls, and reporting of adverse events; (3) these failures increased the risk of regulatory investigation and action; (4) as a result of the Company's misconduct, the U.S. Food and Drug Administration would delay the approval of additional Medtronic MiniMed devices, including the MiniMed 780G; (5) these delays in product approvals, as well as the Company's need to improve its quality control systems, would negatively affect the Company's financial performance and cause Medtronic to fall further behind its competitors; and (6) as a result of the foregoing, defendants' statements about the Company's business, operations, and prospects lacked a reasonable basis.
To learn more contact Vincent Wong, Esq. either via email email@example.com or by telephone at 212.425.1140.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
Vincent Wong, Esq.
39 East Broadway
New York, NY 10002
SOURCE: The Law Offices of Vincent Wong
View source version on accesswire.com: